How Investors Are Reacting To Praxis (PRAX) Advancing Breakthrough NDA Plans With a 2028 Cash Runway

Simply Wall St

Mon, February 16, 2026 at 6:09 AM GMT+9 3 min read

In this article:

PRAX

-4.71%

Praxis Precision Medicines recently presented at Guggenheim’s Emerging Outlook: Biotech Summit 2026 and outlined plans to submit New Drug Applications for ulixacaltamide and relutrigine, both of which have Breakthrough Therapy Designation from the FDA.

Analysts are highlighting ulixacaltamide’s potential in essential tremor, a condition affecting millions of patients, alongside Praxis’s sizeable US$1.50 billions cash position and funding runway into 2028 as key elements of the company’s current appeal.

We’ll now examine how ulixacaltamide’s Breakthrough Therapy Designation and pending NDA filings could reshape Praxis Precision Medicines’ broader investment narrative.

AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there’s still time to get in early.

Praxis Precision Medicines Investment Narrative Recap

To own Praxis today, you need to believe its late stage CNS portfolio can convert ulixacaltamide’s essential tremor opportunity and relutrigine’s epilepsy focus into sustainable commercial products before the cash runway into 2028 is consumed. The near term catalyst is the pair of NDA filings for ulixacaltamide and relutrigine, while the biggest risk is that any regulatory setbacks or delays would extend the company’s loss making period despite its current US$1.50 billions cash position. The Guggenheim summit appearance does not materially change those near term stakes.

The most relevant recent development here is Praxis’s plan to submit two NDAs by mid February 2026 for ulixacaltamide and relutrigine, both with Breakthrough Therapy Designation. This step pulls the regulatory pathway for ulixacaltamide into sharper focus as the central catalyst and frames relutrigine as a follow on driver behind ulixacaltamide’s essential tremor story, while also highlighting that execution across multiple late stage programs remains a core risk.

But alongside these promising catalysts, investors should also be aware that the same ambitious pipeline and trial schedule could still force additional capital raises if…

Read the full narrative on Praxis Precision Medicines (it’s free!)

Praxis Precision Medicines’ narrative projects $724.1 million revenue and $89.5 million earnings by 2029. This requires 359.5% yearly revenue growth and a $362.5 million earnings increase from $-273.0 million today.

Uncover how Praxis Precision Medicines’ forecasts yield a $449.13 fair value, a 42% upside to its current price.

Story Continues  

Exploring Other Perspectives

PRAX 1-Year Stock Price Chart

The most bullish analysts were already assuming revenue might reach about US$2.1 billion and earnings US$783.6 million by 2029, so compared with baseline concerns around execution and cash use, that is a far more optimistic story that could shift again once ulixacaltamide’s NDA outcome and real world essential tremor uptake become clearer.

Explore 4 other fair value estimates on Praxis Precision Medicines - why the stock might be worth over 10x more than the current price!

Build Your Own Praxis Precision Medicines Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

A great starting point for your Praxis Precision Medicines research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.

Our free Praxis Precision Medicines research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Praxis Precision Medicines' overall financial health at a glance.

Want Some Alternatives?

Don’t miss your shot at the next 10-bagger. Our latest stock picks just dropped:

Uncover the next big thing with 29 elite penny stocks that balance risk and reward.

Capitalize on the AI infrastructure supercycle with our selection of the 34 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include PRAX.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info